Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Peptic Ulcer

Free Subscription Articles published in Helicobacter Retrieve available abstracts of 229 articles: HTML format

Single Articles

September 2025
1. SONG Z, Zuo X, Zhang Z, Wang X, et al
   Ten-Day Versus 14-Day Vonoprazan and Amoxicillin Dual Therapy for the Firstline Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial.
   Helicobacter. 2025;30:e70070.
   PubMed     Abstract available
   
   
   
2. CHEN H, Wang Y, Shao Y, Su W, et al
   Multi-Omics Analysis Revealed Characterization of Gastric Microbiome and Metabolome in Helicobacter pylori-Induced Progression of MASLD.
   Helicobacter. 2025;30:e70069.
   PubMed     Abstract available
   
   
   
3. SAVITRI CMA, Matsumoto T, Fauzia KA, Alfaray RI, et al
   Helicobacter pylori Pathogenic Factors and Their Interactions With the Gastric Microbiome.
   Helicobacter. 2025;30:e70072.
   PubMed     Abstract available
   
   
   
4. INNS SJ, Sowerbutts S, Yumnam B, Payne K, et al
   Droplet Digital PCR-Based Detection of Clarithromycin Resistance on Rapid Urease Test Samples Predicts Helicobacter pylori Eradication Success: A New Zealand Cohort Study.
   Helicobacter. 2025;30:e70075.
   PubMed     Abstract available
   
   
   
5. BIBBO S, Ahlstrom G, Pes GM, Graham DY, et al
   Resilience of the Gut Microbiome to Short Proton Pump Inhibitor Therapy With or Without High-Dosage L. reuteri in H. pylori-Infected Adults.
   Helicobacter. 2025;30:e70064.
   PubMed     Abstract available
   
   
   
6. SUGIMOTO M, Sahara S
   Response to "Re-Evaluating the Adverse Events With the Same-Dosage Regimen in Hemodialysis Patients Undergoing Helicobacter pylori Eradication".
   Helicobacter. 2025;30:e70080.
   PubMed    
   
   
   July 2025
7. MYEONG S, Kang D, Kim JS, Cho YK, et al
   Long-Term Risk of Gastric Cancer After Helicobacter pylori Eradication in Gastric Ulcer Patients: A Nationwide Cohort Study in Korea.
   Helicobacter. 2025;30:e70057.
   PubMed     Abstract available
   
   
   
8. AMALIA R, Miftahussurur M, Yamaoka Y
   Response to the Letter by Guo Et al. Regarding "Parietal Cell Antibody Levels Among Chronic Gastritis Patients in a Country With Low Helicobacter pylori Infection".
   Helicobacter. 2025;30:e70055.
   PubMed    
   
   
   
9. YAN TL, Wang JH, Zhu RK, Zhai HL, et al
   Vonoprazan Improves Efficacy of Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter Randomized Controlled Trial.
   Helicobacter. 2025;30:e70056.
   PubMed     Abstract available
   
   
   
10. ZHU Y, Yang J, Fang C, Wang C, et al
    Development and Evaluation of a Multi-Epitope Vaccine Based on P22 Virus-Like Particles Targeting Helicobacter pylori.
    Helicobacter. 2025;30:e70058.
    PubMed     Abstract available
    
    
    
11. MOON SJ, Lee AY, Hwang J, Seo JY, et al
    Helicobacter pylori Eradication in Older Individuals: A Systematic Review and Meta-Analysis.
    Helicobacter. 2025;30:e70059.
    PubMed     Abstract available
    
    
    
12. ALIKHAN H, Levendusky J, Leonick N, Farag M, et al
    Lipidome Characterization Reveals Alterations of Fatty Acid Metabolism in Helicobacter pylori Infection.
    Helicobacter. 2025;30:e70060.
    PubMed     Abstract available
    
    
    
13. TAO L, Qian H, Zhang L, Luo P, et al
    Optimizing Duration and Dosing Frequency of Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori: A Multicenter Randomized Trial.
    Helicobacter. 2025;30:e70062.
    PubMed     Abstract available
    
    
    
14. HOMAN M, Misak Z, Megraud F, Kori M, et al
    Helicobacter pylori Infection in Children Versus Adults, Differences in Management Guidelines: Risks and Benefits of Treatment in Childhood.
    Helicobacter. 2025;30:e70063.
    PubMed     Abstract available
    
    
    
15. KIM HL, Kim DH, Min KW, Son BK, et al
    Arterial Stiffness and Histologically Confirmed Helicobacter pylori Infection in Young Adults.
    Helicobacter. 2025;30:e70067.
    PubMed     Abstract available
    
    
    
16. XIANG L, Zhou Y, Guo X, Mommersteeg MC, et al
    Evaluation of Pepsinogen I, II, Gastrin 17 and Helicobacter pylori IgG in Atrophic Gastritis: A Head-To-Head Comparison of Lateral Flow and Enzyme-Linked Immunosorbent Assays.
    Helicobacter. 2025;30:e70066.
    PubMed     Abstract available
    
    
    
17. KIM YI, Lee JY, Kim CG, Choi IJ, et al
    Helicobacter pylori Infection and Metachronous Gastric Cancer in Elderly Patients With Gastric Cancer Aged >/= 75 Years Who Underwent Endoscopic Submucosal Dissection.
    Helicobacter. 2025;30:e70068.
    PubMed     Abstract available
    
    
    May 2025
18. HE X, Chen H, Chen F, Su W, et al
    Characterization of Fecal Microbial Communities in Patients With Type 2 Diabetes Mellitus Combined With Helicobacter pylori Infection.
    Helicobacter. 2025;30:e70041.
    PubMed     Abstract available
    
    
    
19. MULDER DT, O'Mahony JF, Sun D, van Duuren LA, et al
    The Optimal Age of Helicobacter pylori Screen-and-Treat for Gastric Cancer Prevention in the United States.
    Helicobacter. 2025;30:e70039.
    PubMed     Abstract available
    
    
    
20. YUAN H, Li Y, Wu H, Zhang J, et al
    HIF-1alpha-Induced GPR171 Expression Mediates CCL2 Secretion by Mast Cells to Promote Gastric Inflammation During Helicobacter pylori Infection.
    Helicobacter. 2025;30:e70042.
    PubMed     Abstract available
    
    
    
21. 
    Correction to "Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis".
    Helicobacter. 2025;30:e70044.
    PubMed    
    
    
    
22. REN X, Song Z
    Reply: Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First-Line Helicobacter pylori Eradication Treatment More Effective? A Three-Arm, Multicenter Randomized Clinical Tri
    Helicobacter. 2025;30:e70043.
    PubMed    
    
    
    
23. CHO YS, Kim SM, Kang SH, Moon HS, et al
    Comparison of Therapeutic Outcomes Between Concomitant Therapy and Tailored Therapy for Helicobacter pylori: A Multicenter, Prospective, and Randomized Study.
    Helicobacter. 2025;30:e70040.
    PubMed     Abstract available
    
    
    
24. WANG Y, Zhou K, Zhang Y, Li C, et al
    The Systemic Impact of Helicobacter pylori Infection on the Microbiome of Whole Digestive Tract Based on Mucosal, Gastric Juice, and Fecal Specimens.
    Helicobacter. 2025;30:e70047.
    PubMed     Abstract available
    
    
    
25. DU RC, Zhu YC, Xiao YT, Yang BN, et al
    Assessing the Capabilities of Novel Open-Source Artificial Intelligence-DeepSeek in Helicobacter pylori-Related Queries.
    Helicobacter. 2025;30:e70045.
    PubMed    
    
    
    
26. KASHYAP D, Bagde PH, Singh S, Varshney N, et al
    Gankyrin Inhibition Can Control Helicobacter pylori Generated Gastric Cancer Using In Vivo Xenograft Models.
    Helicobacter. 2025;30:e70046.
    PubMed     Abstract available
    
    
    
27. ISHIBASHI F, Ichita C, Takasu A, Li R, et al
    The Increasing Trend of the Generational Helicobacter pylori-Naive Prevalence Among Japanese Individuals Born Between 1925 and 2015: A Systematic Review and Meta-Regression Analysis.
    Helicobacter. 2025;30:e70052.
    PubMed     Abstract available
    
    
    
28. PENG R, Cai P, Zhang Z, Lv S, et al
    Efficacy of Three Amoxicillin Doses in Vonoprazan Dual Therapy for Helicobacter pylori Eradication: A Randomized Noninferiority Trial.
    Helicobacter. 2025;30:e70050.
    PubMed     Abstract available
    
    
    
29. YU Z, Shen W, Lou G, Li Y, et al
    Authors' Reply to the Letter on "Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First-Line Helicobacter pylori Eradication Treatment More Effective? A Three-Arm, Multicent
    Helicobacter. 2025;30:e70049.
    PubMed     Abstract available
    
    
    
30. SUGIMOTO M, Rimbara E, Murata M, Yamaoka Y, et al
    Roles of Gastric Non-Helicobacter pylori Helicobacter Species in Gastric Disease Development: A Review.
    Helicobacter. 2025;30:e70051.
    PubMed     Abstract available
    
    
    
31. GUO X, Spaander MCW, Fuhler GM
    Letter to the Editor: "Parietal Cell Antibody Levels Among Chronic Gastritis Patients in a Country With Low Helicobacter pylori Infection: Epidemiology, Histopathological Features, and H. pylori Infection".
    Helicobacter. 2025;30:e70053.
    PubMed    
    
    
    
32. MISHRA V, Dash D, Panda AK, Pathak SK, et al
    Letter to the Editor: Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis-Authors' Reply.
    Helicobacter. 2025;30:e70054.
    PubMed    
    
    
    March 2025
33. SUBSOMWONG P, Asano K, Akada J, Matsumoto T, et al
    Proteomic Profiling of Extracellular Vesicles Reveals Potential Biomarkers for Helicobacter pylori Infection and Gastric Cancer.
    Helicobacter. 2025;30:e70022.
    PubMed     Abstract available
    
    
    
34. SU MS, Dickins B, Kiang FY, Tsai WJ, et al
    Flagellar Assembly Factor FliW2 De-Represses Helicobacter pylori FlaA-Mediated Motility by Allosteric Obstruction of Global Regulator CsrA.
    Helicobacter. 2025;30:e70019.
    PubMed     Abstract available
    
    
    
35. FRIAS-ORDONEZ JS, Riquelme A, Marulanda-Fernandez H, Otero-Parra L, et al
    Helicobacter pylori and Colorectal Cancer: Meeting Sir Austin Bradford Hill's Causality Criteria.
    Helicobacter. 2025;30:e70024.
    PubMed     Abstract available
    
    
    
36. ZHU M, Xu X, Cai P, Wang T, et al
    Global Population Structure, Virulence Factors and Antibiotic Resistance of Helicobacter pylori: A Pooled Analysis of 4067 Isolates From 76 Countries.
    Helicobacter. 2025;30:e70025.
    PubMed     Abstract available
    
    
    
37. JIANG Y, Yan H, Cui J, Yang K, et al
    Artificial Intelligence in Endoscopy for Predicting Helicobacter pylori Infection: A Systematic Review and Meta-Analysis.
    Helicobacter. 2025;30:e70026.
    PubMed     Abstract available
    
    
    
38. ZHOU BG, Li YY, Ding YB
    Letter to the Editor: "Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis".
    Helicobacter. 2025;30:e70027.
    PubMed    
    
    
    
39. ZHANG Y, Yan Z, Jiao Y, Feng Y, et al
    Innate Immunity in Helicobacter pylori Infection and Gastric Oncogenesis.
    Helicobacter. 2025;30:e70015.
    PubMed     Abstract available
    
    
    
40. TEPES B, Jurecic NB, Denkovski M, Vujasinovic M, et al
    First-Line Therapy for Helicobacter pylori in Slovenia: Data From 2013 to 2023 of the European Registry on H. pylori Management.
    Helicobacter. 2025;30:e70029.
    PubMed     Abstract available
    
    
    
41. KIM MJ, Je Y, Chun J, Youn YH, et al
    Helicobacter pylori Eradication Is Associated With a Reduced Risk of Metachronous Gastric Neoplasia by Restoring Immune Function in the Gastric Mucosa.
    Helicobacter. 2025;30:e70030.
    PubMed     Abstract available
    
    
    
42. TEJEDOR-TEJADA J, Martinez-Dominguez SJ, Hernandez L, Cano-Catala A, et al
    Management of Helicobacter pylori Infection in Spain Beyond the Data Collected in the European Registry on H. pylori Management (Hp-EuReg): Results of a Nationwide Survey.
    Helicobacter. 2025;30:e70028.
    PubMed     Abstract available
    
    
    
43. PRIADKO K, Gibaud SA, Druet A, Galmiche L, et al
    Real-Time PCR Helicobacter pylori Test in Comparison With Culture and Histology for Helicobacter pylori Detection and Identification of Resistance to Clarithromycin: A Single-Center Real-Life Study.
    Helicobacter. 2025;30:e70031.
    PubMed     Abstract available
    
    
    
44. NAN XP, Zhao HY, Guo LN, Zheng RQ, et al
    Seven-Day Versus 14-Day Tegoprazan and Tetracycline-Containing Quadruple Therapy for First-Line Eradication of Helicobacter pylori Infection: A Randomized, Open-Label, Noninferiority Trial.
    Helicobacter. 2025;30:e70036.
    PubMed     Abstract available
    
    
    
45. GUTIERREZ-RAMIREZ L, Garcia-Dionisio SL, Feo-Ortega S, Gonzalez-Cervera J, et al
    The Association Between Helicobacter pylori Infection and Eosinophilic Esophagitis: Systematic Review and Meta-Analysis.
    Helicobacter. 2025;30:e70038.
    PubMed     Abstract available
    
    
    
46. AMALIA R, Miftahussurur M, Syam AF, Uchida T, et al
    Parietal Cell Antibody Levels Among Chronic Gastritis Patients in a Country With Low Helicobacter pylori Infection: Epidemiology, Histopathological Features, and H. pylori Infection.
    Helicobacter. 2025;30:e70035.
    PubMed     Abstract available
    
    
    
47. LI JY, Song JC, Tian X, Liu YH, et al
    Comparison of Cefuroxime-Based Dual Therapy With Quadruple Therapy in Helicobacter pylori-Infected Treatment-Naive Patients: A Prospective, Multicenter, Randomized Controlled Trial.
    Helicobacter. 2025;30:e70037.
    PubMed     Abstract available
    
    
    
48. KASTUAR S, Devalaraju S, Cifuentes JG, El-Serag HB, et al
    Impact of an Electronic Medical Record Quality Improvement Intervention on Helicobacter pylori Treatment and Eradication Rates in a U.S. Hospital System.
    Helicobacter. 2025;30:e70034.
    PubMed     Abstract available
    
    
    
49. WANG H, Kong Q, Zhang Q, Zhang L, et al
    Efficacy and Safety of Cefuroxime-Tetracycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Eradication in Penicillin-Allergic Patients: A Multicenter Randomized Controlled Trial.
    Helicobacter. 2025;30:e70033.
    PubMed     Abstract available
    
    
    January 2025
50. MORI H, Nishizawa T, Morioka K, Kato M, et al
    Should Metronidazole Be Included in Second-Line Treatment After Standard Triple Therapy for Helicobacter pylori?: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Helicobacter. 2025;30:e70010.
    PubMed     Abstract available
    
    
    
51. NESS A, Levi Z, Belfer RG, Dickman R, et al
    Improvement in Helicobacter pylori Eradication Among Adults Receiving Semaglutide: A Population-Based Propensity-Score-Adjusted Analysis.
    Helicobacter. 2025;30:e70014.
    PubMed     Abstract available
    
    
    
52. KIM Y, Lee JH, Na HK, Jung KW, et al
    Efficacy of Rifabutin-Based Helicobacter pylori Eradication Regimen in Korea With High Prevalence of Tuberculosis Infection.
    Helicobacter. 2025;30:e70011.
    PubMed     Abstract available
    
    
    
53. HSU JY, Wu UI, Wang JT, Sheng WH, et al
    Managing Helicobacter pylori as an Infectious Disease: Implementation of Antimicrobial Stewardship.
    Helicobacter. 2025;30:e70013.
    PubMed     Abstract available
    
    
    
54. WANG Y, Gong X, Lai Q, Fang H, et al
    The Accuracy of Melting Curve-Based Multiplex Real-Time PCR for Diagnosing Helicobacter pylori Resistance to Clarithromycin and Levofloxacin in Stool Specimens.
    Helicobacter. 2025;30:e70012.
    PubMed     Abstract available
    
    
    
55. YU LY, Kuo YC, Lin YC, Hu KC, et al
    Interpretation the Results of Eradicating Helicobacter pylori Infection Causing Colorectal Cancer Could Be Cautious.
    Helicobacter. 2025;30:e70017.
    PubMed    
    
    
    
56. YU Z, Liu X, Qiao J, Shen W, et al
    Is Tailored Bismuth Quadruple Therapies (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First-Line Helicobacter pylori Eradication Treatment More Effective? A Three-Arm, Multicenter Randomized Clinical Trial.
    Helicobacter. 2025;30:e70018.
    PubMed     Abstract available
    
    
    
57. KUANG Z, Wu Y, Xie X, Zhao X, et al
    Advances in Helicobacter pylori Antimicrobial Resistance Detection: From Culture-Based to Multi-Omics-Based Technologies.
    Helicobacter. 2025;30:e70007.
    PubMed     Abstract available
    
    
    
58. ABDUN MA, Xu L, Li XT, Mekky A, et al
    Global Prevalence of Helicobacter pylori Infection-Associated Gastric Preneoplastic Lesions in Pediatric Patients: A Systematic Review and Meta-Analysis.
    Helicobacter. 2025;30:e70021.
    PubMed     Abstract available
    
    
    
59. GIDDINGS HJ, Teodosio A, Jones J, McMurray JL, et al
    The Gastric Microbiota Invade the Lamina Propria in Helicobacter pylori-Associated Gastritis and Precancer.
    Helicobacter. 2025;30:e70016.
    PubMed     Abstract available
    
    
    
60. HU KY, Tseng PH, Liou JM, Tu CH, et al
    Rebound of Reflux-Related Symptoms After Helicobacter pylori Eradication in Patients With Gastroesophageal Reflux Disease: A Prospective Randomized Study.
    Helicobacter. 2025;30:e70023.
    PubMed     Abstract available
    
    
    
61. LIU YX, Liu HN, Liu HQ, Yang YY, et al
    Vonoprazan-Amoxicillin Dual Therapy Versus Drug Sensitivity-Based Individualized Therapy as a Rescue Regimen for Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial.
    Helicobacter. 2025;30:e70009.
    PubMed     Abstract available
    
    
    November 2024
62. DO TMP, Tran THT, Nguyen VT, Chu TPM, et al
    Efficacy of Bismuth Quadruple Therapy in the Treatment of Helicobacter pylori-Infected Peptic Ulcer Children in Vietnam.
    Helicobacter. 2024;29:e13149.
    PubMed     Abstract available
    
    
    
63. MATSUMOTO S, Sugimoto M, Terai T, Maruyama Y, et al
    Map-Like Redness Development After Eradication Therapy for Helicobacter pylori Infection: Prospective Multicenter Observational Study.
    Helicobacter. 2024;29:e13146.
    PubMed     Abstract available
    
    
    
64. JUNG BW, Kim YJ, Park CH
    Nationwide Trends in Helicobacter pylori Eradication Therapies in Korea: Impact of Guideline Updates on Treatment Practices.
    Helicobacter. 2024;29:e13152.
    PubMed     Abstract available
    
    
    
65. MASHIKO S, Ifeanyi Smith S, Rose U, Abiodun OJ, et al
    Helicobacter pylori Management in Africa: A Survey of Diagnostic, Treatment, and Related Resources.
    Helicobacter. 2024;29:e13153.
    PubMed     Abstract available
    
    
    
66. BENITO BM, Nyssen OP, Gisbert JP
    Efficacy and Safety of Vonoprazan in Dual/Triple/Quadruple Regimens Both in First-Line and Rescue Therapy for Helicobacter pylori Eradication: A Systematic Review With Meta-Analysis.
    Helicobacter. 2024;29:e13148.
    PubMed     Abstract available
    
    
    
67. LIN X, Huang H, Liu Y, Zeng Y, et al
    Tegoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Prospective, Randomized, Multicenter Study in Fujian, China.
    Helicobacter. 2024;29:e13151.
    PubMed     Abstract available
    
    
    
68. OUYANG M, Zou S, Cheng Q, Shi X, et al
    Comparative Efficacy and Safety of Potassium-Competitive Acid Blockers and Proton Pump Inhibitors for First-Line Helicobacter pylori Eradication Therapy: A Systematic Review and Network Meta-Analysis.
    Helicobacter. 2024;29:e13150.
    PubMed     Abstract available
    
    
    
69. LIU Q, Sadr-Azodi O, Engstrand L, Fall K, et al
    Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population-Based Nationwide Cohort Study in Sweden.
    Helicobacter. 2024;29:e70001.
    PubMed     Abstract available
    
    
    
70. REQUENA D, Ribas E, Gilman RH, Cabrera L, et al
    Effects of High Altitude and Diet on Gastric Disease Severity in Helicobacter pylori Infection in Peru.
    Helicobacter. 2024;29:e13147.
    PubMed     Abstract available
    
    
    
71. MANFREDI M, Ravikumara M
    Helicobacter pylori Infection in Children: To Eradicate or Not to Eradicate?
    Helicobacter. 2024;29:e70002.
    PubMed     Abstract available
    
    
    
72. NOH JH, Choi KD, Na HK, Ahn JY, et al
    Effect of Macrolide Exposure on Tailored Helicobacter pylori Eradication Therapy and Antibiotic Resistance Profiles: A Prospective Study Using the Drug Utilization Review System.
    Helicobacter. 2024;29:e70003.
    PubMed     Abstract available
    
    
    
73. WANG X, Chan XF, Go Y, Wang Y, et al
    Combatting Helicobacter pylori: A Focus on Nanomaterials.
    Helicobacter. 2024;29:e70004.
    PubMed     Abstract available
    
    
    
74. MISHRA V, Dash D, Panda AK, Pathak SK, et al
    Efficacy of Lactobacillus spp. Supplementation in Helicobacter pylori Eradication: A Systematic Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis.
    Helicobacter. 2024;29:e70006.
    PubMed     Abstract available
    
    
    September 2024
75. LE THI TG, Werkstetter K, Kotilea K, Bontems P, et al
    Factors Associated With Decision to Treat or Not to Treat Helicobacter pylori Infection in Children: Data From the EuroPedHp Registry.
    Helicobacter. 2024;29:e13134.
    PubMed     Abstract available
    
    
    
76. CHEUNG KS, Lyu T, Deng Z, Han S, et al
    Vonoprazan Dual or Triple Therapy Versus Bismuth-Quadruple Therapy as First-Line Therapy for Helicobacter pylori Infection: A Three-Arm, Randomized Clinical Trial.
    Helicobacter. 2024;29:e13133.
    PubMed     Abstract available
    
    
    
77. SUN L, Liu M, Gong Y, Zhai K, et al
    Rapid Antimicrobial Susceptibility Test of Helicobacter pylori to Metronidazole via Single-Cell Raman Spectrometry.
    Helicobacter. 2024;29:e13136.
    PubMed     Abstract available
    
    
    
78. 
    Correction to "Long-Term Effects of Fecal Microbiota Transplantation on Gut Microbiota After Helicobacter pylori Eradication With Bismuth Quadruple Therapy: A Randomized Controlled Trial".
    Helicobacter. 2024;29:e13127.
    PubMed    
    
    
    
79. LIU N, Luo Q, Gou L, Shen X, et al
    Knowledge and Practices of Helicobacter pylori Infection Management Among Physicians in Gansu Province, China: A Cross-Sectional Study.
    Helicobacter. 2024;29:e13137.
    PubMed     Abstract available
    
    
    
80. HUANG Y, Qiu S, Guo Y, Chen J, et al
    Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Real-World Evidence Study.
    Helicobacter. 2024;29:e13138.
    PubMed     Abstract available
    
    
    
81. BOTIJA G, Galicia G, Martinez B, Cuadrado C, et al
    Efficacy of Bismuth Therapy in Eradicating Helicobacter pylori in Children-Data From the RENIHp Registry.
    Helicobacter. 2024;29:e13142.
    PubMed     Abstract available
    
    
    
82. REUM CHOE A, Tae CH, Choi M, Shim KN, et al
    Systematic Review and Meta-Analysis: Bismuth Enhances the Efficacy for Eradication of Helicobacter pylori.
    Helicobacter. 2024;29:e13141.
    PubMed     Abstract available
    
    
    
83. WANG Z, Hu Y, Fei R, Han W, et al
    Tracking the Helicobacter pylori Epidemic in Adults and Children in China.
    Helicobacter. 2024;29:e13139.
    PubMed     Abstract available
    
    
    
84. DUAN M, Kong Q, Wang H, Li Y, et al
    Optimal Duration of Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
    Helicobacter. 2024;29:e13144.
    PubMed     Abstract available
    
    
    
85. LAI J, Angulmaduwa S, Kim MA, Kim A, et al
    Influence of oipA Phase Variation on Virulence Phenotypes Related to Type IV Secretion System in Helicobacter pylori.
    Helicobacter. 2024;29:e13140.
    PubMed     Abstract available
    
    
    
86. LEE JW, Kim N, Lee J, Jo SY, et al
    Efficacy of Tegoprazan-Containing Sequential Eradication Treatment Compared to Esomeprazole-Containing Sequential Eradication of Helicobacter pylori in South Korea, a Region With High Antimicrobial Resistance: A Prospective, Randomized, Single Tertiar
    Helicobacter. 2024;29:e13143.
    PubMed     Abstract available
    
    
    
87. 
    Correction to Antimicrobial Resistance of Helicobacter pylori Isolated From Latin American Children and Adolescents (2008-2023): A Systematic Review.
    Helicobacter. 2024;29:e13145.
    PubMed    
    
    
    July 2024
88. LI B, He J, Zhang R, Liu S, et al
    Integrin-Linked Kinase in the Development of Gastric Tumors Induced by Helicobacter pylori: Regulation and Prevention Potential.
    Helicobacter. 2024;29:e13109.
    PubMed     Abstract available
    
    
    
89. LI XT, Xu L, Zhang C, Qi YB, et al
    Improved Patient Adherence to Family-Based Helicobacter pylori Infection Control and Management Strategy in Central China and Its Influencing Factors.
    Helicobacter. 2024;29:e13114.
    PubMed     Abstract available
    
    
    
90. JAUVAIN M, Lepied G, Benejat L, Roudier N, et al
    Effect of Lactobacillus gasseri BIO6369 and Lacticaseibacillus rhamnosus BIO5326 on Gastric Carcinogenesis Induced by Helicobacter pylori Infection.
    Helicobacter. 2024;29:e13108.
    PubMed     Abstract available
    
    
    
91. MARTINEZ-DOMINGUEZ SJ, Nyssen OP, Lanas A, Alfaro E, et al
    Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg).
    Helicobacter. 2024;29:e13111.
    PubMed     Abstract available
    
    
    
92. CABRERA C, Torres J, Serrano CA, Gallardo P, et al
    Antimicrobial Resistance of Helicobacter pylori Isolated From Latin American Children and Adolescents (2008-2023): A Systematic Review.
    Helicobacter. 2024;29:e13101.
    PubMed     Abstract available
    
    
    
93. ZHAO JT, Zhang Y, Wang XW, Zou PY, et al
    Long-term effects of fecal microbiota transplantation on gut microbiota after Helicobacter pylori eradication with bismuth quadruple therapy: A randomized controlled trial.
    Helicobacter. 2024;29:e13079.
    PubMed     Abstract available
    
    
    
94. QIU S, Huang Y, Chen J, Guo Y, et al
    Vonoprazan-Amoxicillin Dual Therapy With Different Amoxicillin Administration Regimens for Helicobacter pylori Treatment: A Randomized Controlled Trial.
    Helicobacter. 2024;29:e13118.
    PubMed     Abstract available
    
    
    
95. DORE MP, Hernaez R, Graham DY
    Self-Correcting Method for Highly Effective Office-Based Helicobacter pylori Therapy Using Cumulative Test of Cure Data.
    Helicobacter. 2024;29:e13112.
    PubMed     Abstract available
    
    
    
96. HU Y, Lai Y, Liao F, Shu X, et al
    Assessing Accuracy of ChatGPT on Addressing Helicobacter pylori Infection-Related Questions: A National Survey and Comparative Study.
    Helicobacter. 2024;29:e13116.
    PubMed     Abstract available
    
    
    
97. MELNIK P, Weintraub I, Shamaly H, Cohen S, et al
    Helicobacter pylori-Associated Extranodal Marginal Zone Lymphoma of Mucosa-Associated Tissue in Children: A Multicenter Case Series.
    Helicobacter. 2024;29:e13113.
    PubMed     Abstract available
    
    
    
98. MA Y, Zhou X, Liu Y, Xu S, et al
    An Economic Evaluation of Family-Based Versus Traditional Helicobacter pylori Screen-and-Treat Strategy: Based on Real-World Data and Microsimulation Model.
    Helicobacter. 2024;29:e13123.
    PubMed     Abstract available
    
    
    
99. 
    Correction to Indications of Helicobacter pylori Eradication Treatment and Its Influence on Prescriptions and Effectiveness (Hp-EuReg).
    Helicobacter. 2024;29:e13124.
    PubMed    
    
    
    
100. LIU Z, Li H, Huang X, Liu Q, et al
     Animal Models of Helicobacter pylori Infection and Vaccines: Current Status and Future Prospects.
     Helicobacter. 2024;29:e13119.
     PubMed     Abstract available
     
     
     
101. ZHOU S, Zheng Z, Wang L, Song W, et al
     Correlation of FUT3 and FUT6 Gene Polymorphisms With Helicobacter pylori Infection.
     Helicobacter. 2024;29:e13122.
     PubMed     Abstract available
     
     
     
102. ZENG S, Kong Q, Wu X, Ma T, et al
     Artificial Intelligence-Generated Patient Education Materials for Helicobacter pylori Infection: A Comparative Analysis.
     Helicobacter. 2024;29:e13115.
     PubMed     Abstract available
     
     
     
103. DING YM, Zhang QM, Li RL, Han ZX, et al
     Tetracycline Three Times Daily Versus Four Times Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial.
     Helicobacter. 2024;29:e13121.
     PubMed     Abstract available
     
     
     
104. YANG P, Jiang J
     Letter to the Editor Regarding the Article: "Exploring the Capacities of ChatGPT: A Comprehensive Evaluation of Its Accuracy and Repeatability in Addressing Helicobacter pylori-Related Queries".
     Helicobacter. 2024;29:e13131.
     PubMed    
     
     
     
105. KIM JS, Kim BW, Kim JI, Chung WC, et al
     Empirical Therapy Versus Tailored Therapy of Helicobacter pylori in Korea: Results of the K-CREATE Study.
     Helicobacter. 2024;29:e13126.
     PubMed     Abstract available
     
     
     
106. KOWADA A
     Cost-Effectiveness of Population-Based Helicobacter pylori Screening With Eradication for Optimal Age of Implementation.
     Helicobacter. 2024;29:e13120.
     PubMed     Abstract available
     
     
     
107. ZHANG Z, Cui M, Ji X, Su G, et al
     Candidate Antigens and the Development of Helicobacter pylori Vaccines.
     Helicobacter. 2024;29:e13128.
     PubMed     Abstract available
     
     
     
108. CHIU YT, Lee FJ, Kuo CY, Chen YT, et al
     Seven-Day Vonoprazan-Based Triple Therapy as First-Line Helicobacter pylori Treatment in Comparison With Extended Sequential Therapy: A Randomized Controlled Trial.
     Helicobacter. 2024;29:e13129.
     PubMed     Abstract available
     
     
     
109. XIA C, Chen Z, Chen Y, Wei F, et al
     Effects of Latilactobacillus sakei LZ217 on Gastric Mucosal Colonization, Metabolic Interference, and Urease Expression in Helicobacter pylori Infection.
     Helicobacter. 2024;29:e13130.
     PubMed     Abstract available
     
     
     
110. IWATA E, Sugimoto M, Asaoka D, Hojo M, et al
     Characteristics of Helicobacter pylori Eradication Therapy in Patients 80 Years or Older Living in a Metropolitan Area: A Multicenter Retrospective Study.
     Helicobacter. 2024;29:e13125.
     PubMed     Abstract available
     
     
     May 2024
111. JUNG K, Jee SR, Lee MW, Koh M, et al
     Comparison of Helicobacter pylori eradication rates between 7 and 14 days of tailored therapy according to clarithromycin resistance test: A randomized, multicenter, non-inferiority study.
     Helicobacter. 2024;29:e13084.
     PubMed     Abstract available
     
     
     
112. KAOUAH Z, Buyck JM, Pichon M, Burucoa C, et al
     In vitro efficacy of combinations of antibiotics used in clinical practice on clinical isolates of Helicobacter pylori.
     Helicobacter. 2024;29:e13081.
     PubMed     Abstract available
     
     
     
113. ARFI S, Sharma P, Kumar M, Mehra S, et al
     Antibiotic susceptibility pattern of Helicobacter pylori against eight antibiotics: A study from North India.
     Helicobacter. 2024;29:e13093.
     PubMed     Abstract available
     
     
     
114. XIE J, Peng J, Liu D, Zeng R, et al
     Treatment failure is a key factor in the development of Helicobacter pylori resistance.
     Helicobacter. 2024;29:e13091.
     PubMed     Abstract available
     
     
     
115. TALAYEV V, Svetlova M, Zaichenko I, Voronina E, et al
     CCR6(+) T helper cells and regulatory T cells in the blood and gastric mucosa during Helicobacter pylori infection.
     Helicobacter. 2024;29:e13097.
     PubMed     Abstract available
     
     
     
116. KAYAMBA V, Munshi H, Hankolwe MN, Kaluba Kavimba C, et al
     Nationwide survey of Helicobacter pylori seropositivity and gastric atrophy in Zambia.
     Helicobacter. 2024;29:e13096.
     PubMed     Abstract available
     
     
     
117. KOTILEA K, Romano C, Miele E, Kindermann A, et al
     Helicobacter pylori infection found during upper endoscopy performed for the diagnosis of celiac, inflammatory bowel diseases, and eosinophilic esophagitis: A multicenter pediatric European study.
     Helicobacter. 2024;29:e13092.
     PubMed     Abstract available
     
     
     
118. ZHANG C, Qi YB, Hu RB, Xu L, et al
     Family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are highly cost-effective in preventing multiple upper gastrointestinal diseases in Chinese population at national level.
     Helicobacter. 2024;29:e13063.
     PubMed     Abstract available
     
     
     
119. HAN Z, Zhang Q, Mirza IA, Ding Y, et al
     Efficacy of Tetracycline Three Times Daily was Comparable to That of Four Times Daily for Helicobacter pylori Rescue Treatment: A Multicenter, Noninferiority, Randomized Controlled Trial.
     Helicobacter. 2024;29:e13102.
     PubMed     Abstract available
     
     
     
120. YU J, He Y, Yao W, Liu T, et al
     Helicobacter pylori CagA Promotes the Formation of Gallstones by Increasing the Permeability of Gallbladder Epithelial Cells.
     Helicobacter. 2024;29:e13100.
     PubMed     Abstract available
     
     
     
121. LAI Y, Liao F, Zhao J, Zhu C, et al
     Exploring the capacities of ChatGPT: A comprehensive evaluation of its accuracy and repeatability in addressing helicobacter pylori-related queries.
     Helicobacter. 2024;29:e13078.
     PubMed     Abstract available
     
     
     
122. KONG Q, Mirza IA, Zhang X, Song X, et al
     Fourteen-Day Tegoprazan-Amoxicillin Dual Therapy as the First-Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial.
     Helicobacter. 2024;29:e13098.
     PubMed     Abstract available
     
     
     
123. YU Y, Xue J, Lin F, Liu D, et al
     Global Primary Antibiotic Resistance Rate of Helicobacter pylori in Recent 10 years: A Systematic Review and Meta-Analysis.
     Helicobacter. 2024;29:e13103.
     PubMed     Abstract available
     
     
     
124. JAFARZADEH A, Jafarzadeh Z, Nemati M, Yoshimura A, et al
     The Interplay Between Helicobacter pylori and Suppressors of Cytokine Signaling (SOCS) Molecules in the Development of Gastric Cancer and Induction of Immune Response.
     Helicobacter. 2024;29:e13105.
     PubMed     Abstract available
     
     
     
125. MOGES ESKEZIYAW B, Waihenya R, Maina N, Muuo Nzou S, et al
     Immunoinformatics-Based Designing of Novel and Potent Multi-Epitope PSA D15 and Cag11 Immunogens for Helicobacter pylori Immunodiagnostic Assay Development.
     Helicobacter. 2024;29:e13104.
     PubMed     Abstract available
     
     
     
126. DORE MP, Meloni G, Bassu I, Pes GM, et al
     Helicobacter pylori Infection Does Not Protect Against Allergic Diseases: Evidence From a Pediatric Cohort From Northern Sardinia, Italy.
     Helicobacter. 2024;29:e13107.
     PubMed     Abstract available
     
     
     
127. SAHARA S, Sugimoto M, Murata M, Iwata E, et al
     Eradication Therapy for Helicobacter pylori Infection in Patients Receiving Hemodialysis: Review.
     Helicobacter. 2024;29:e13106.
     PubMed     Abstract available
     
     
     March 2024
128. YANG H, Zhang M, Ma G, Yang J, et al
     Meta-analysis of Helicobacter pylori eradication therapy using vonoprazan as an acid suppressor compared with bismuth quadruple therapy.
     Helicobacter. 2024;29:e13059.
     PubMed     Abstract available
     
     
     
129. CHEN S, Zhao H, Tian Y, Wu Q, et al
     Antagonizing roles of SHP1 in the pathogenesis of Helicobacter pylori infection.
     Helicobacter. 2024;29:e13066.
     PubMed     Abstract available
     
     
     
130. VANGRAVS R, Mezmale L, Slefarska-Wolak D, Dauss E, et al
     Volatilomic signatures of different strains of Helicobacter pylori.
     Helicobacter. 2024;29:e13064.
     PubMed     Abstract available
     
     
     
131. TSUDA M, Watanabe Y, Oikawa R, Watanabe R, et al
     Impact of mixed-infection rate of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains on the success rate of clarithromycin-based eradication treatment.
     Helicobacter. 2024;29:e13062.
     PubMed     Abstract available
     
     
     
132. APOORVA E, Jacob R, Rao DN, Kumar S, et al
     Helicobacter pylori enhances HLA-C expression in the human gastric adenocarcinoma cells AGS and can protect them from the cytotoxicity of natural killer cells.
     Helicobacter. 2024;29:e13069.
     PubMed     Abstract available
     
     
     
133. PEYPAR MH, Yeganeh AV, Ramazani A, Alizadeh A, et al
     Oral immunotherapy for Helicobacter pylori: Can it be trusted? A systematic review.
     Helicobacter. 2024;29:e13067.
     PubMed     Abstract available
     
     
     
134. OKAMURA T, Iwaya Y, Nagaya T, Horiuchi K, et al
     Diagnosis by combination of endoscopic findings helps differentiate non-Helicobacter pylori Helicobacter-infected gastritis from Helicobacter pylori-infected gastritis.
     Helicobacter. 2024;29:e13070.
     PubMed     Abstract available
     
     
     
135. LUO Q, Liu C, Zhang A, Zhang D, et al
     Research progress in photodynamic therapy for Helicobacter pylori infection.
     Helicobacter. 2024;29:e13068.
     PubMed     Abstract available
     
     
     
136. MI C, Suo B, Tian X, Wang Y, et al
     Application of cefuroxime in the eradication therapy of Helicobacter pylori infection: A review article.
     Helicobacter. 2024;29:e13073.
     PubMed     Abstract available
     
     
     
137. LARA ICAZA JD, Tapia RL, Triana CTC, Ramirez LCR, et al
     Refractoriness to anti-Helicobacter pylori treatment attributed to phenotypic resistance patterns in patients with gastroduodenopathy in Guayaquil-Ecuador.
     Helicobacter. 2024;29:e13060.
     PubMed     Abstract available
     
     
     
138. LIU J, Jia J, Shi T, Bai Y, et al
     Evaluating the potency of zoliflodacin against Helicobacter pylori: In vitro activity and conserved GyrB target.
     Helicobacter. 2024;29:e13075.
     PubMed     Abstract available
     
     
     
139. MOFIDIFAR S, Yadegar A, Karimi-Jafari MH
     A reconstructed genome-scale metabolic model of Helicobacter pylori for predicting putative drug targets in clarithromycin and rifampicin resistance conditions.
     Helicobacter. 2024;29:e13074.
     PubMed     Abstract available
     
     
     
140. GUAN X, Ning J, Fu W, Wang Y, et al
     Helicobacter pylori with trx1 high expression promotes gastric diseases via upregulating the IL23A/NF-kappaB/IL8 pathway.
     Helicobacter. 2024;29:e13072.
     PubMed     Abstract available
     
     
     
141. CHEN J, Zhang Y, Min H, Zhi J, et al
     Dynamic changes in the gut microbiota after bismuth quadruple therapy and high-dose dual therapy for Helicobacter pylori eradication.
     Helicobacter. 2024;29:e13077.
     PubMed     Abstract available
     
     
     
142. AMIOT A, Hacoon J, Heluwaert F, Mion F, et al
     14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial.
     Helicobacter. 2024;29:e13076.
     PubMed     Abstract available
     
     
     
143. STERBENC A, Godnov U, Vodicar PM, Simcic S, et al
     Prevalence of Helicobacter pylori infection among Slovenian children and adolescents: A prospective cohort study.
     Helicobacter. 2024;29:e13082.
     PubMed     Abstract available
     
     
     
144. KATO M, Ono S, Kawada K, Dohi O, et al
     Diagnostic performance of linked color imaging for gastric cancer by Helicobacter pylori infection status: A subanalysis of the large-scale, multicenter randomized controlled trial LCI-FIND.
     Helicobacter. 2024;29:e13080.
     PubMed     Abstract available
     
     
     
145. AGAWA H, Tsukadaira T, Kobayashi N, Kodaira H, et al
     Four cases of non-Helicobacter pylori Helicobacter-infected gastritis with duodenal spiral bacilli.
     Helicobacter. 2024;29:e13083.
     PubMed     Abstract available
     
     
     January 2024
146. VON MUHLENBROCK C, Cordova A, Nunez P, Pacheco N, et al
     Eradication rate and adherence with high-dose amoxicillin and proton pump inhibitor as first-line treatment for Helicobacter pylori infection: Experience from University Hospital in Chile.
     Helicobacter. 2024;29:e13052.
     PubMed     Abstract available
     
     
     
147. MARZHOSEYNI Z, Mousavi MJ, Ghotloo S
     Helicobacter pylori antigens as immunomodulators of immune system.
     Helicobacter. 2024;29:e13058.
     PubMed     Abstract available
     
     
     
148. DUTTA S, Jain S, Das K, Verma P, et al
     Primary antibiotic resistance of Helicobacter pylori in India over the past two decades: A systematic review.
     Helicobacter. 2024;29:e13057.
     PubMed     Abstract available
     
     
     
149. TIRGAR FAKHERI S, Shokri-Afra H, Graham DY, Bari Z, et al
     A pilot study evaluating high dose esomeprazole, bismuth subcitrate and amoxicillin for eradicating Helicobacter pylori infection in Iran.
     Helicobacter. 2024;29:e13061.
     PubMed     Abstract available
     
     
     
150. LO HY, Yang YJ
     Seroprevalence of Helicobacter pylori infection among schoolchildren in southern Taiwan-A 20-year longitudinal follow-up.
     Helicobacter. 2024;29:e13049.
     PubMed     Abstract available
     
     
     
151. WU X, Duan M, Kong Q, Zeng S, et al
     Clarifying varied Helicobacter pylori eradication therapies: A comprehensive review.
     Helicobacter. 2024;29:e13048.
     PubMed     Abstract available
     
     
     
152. JU KP, Kong QZ, Li YY, Li YQ, et al
     Low-dose or high-dose amoxicillin in vonoprazan-based dual therapy for Helicobacter pylori eradication? A systematic review and meta-analysis.
     Helicobacter. 2024;29:e13054.
     PubMed     Abstract available
     
     
     
153. MATSUMOTO S, Sugimoto M, Fukuzawa M, Uesugi N, et al
     Risk of map-like redness development after eradication therapy for Helicobacter pylori infection.
     Helicobacter. 2024;29:e13046.
     PubMed     Abstract available
     
     
     
154. KONG QZ, Ju KP, Wan M, Liu J, et al
     Comparative analysis of large language models in medical counseling: A focus on Helicobacter pylori infection.
     Helicobacter. 2024;29:e13055.
     PubMed     Abstract available
     
     
     
155. HU Y, Huang XH, Zhou B, Liu ML, et al
     Vonoprazan and amoxicillin dual therapy for 14 days as the first-line treatment of Helicobacter pylori infection: A non-inferiority, randomized clinical trial.
     Helicobacter. 2024;29:e13045.
     PubMed     Abstract available
     
     
     November 2023
156. DU RC, Hu YX, Ouyang Y, Ling LX, et al
     Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis.
     Helicobacter. 2023 Nov 30:e13039. doi: 10.1111/hel.13039.
     PubMed     Abstract available
     
     
     
157. LIANG Y, Yang Y, Nong R, Huang H, et al
     Do atrophic gastritis and intestinal metaplasia reverse after Helicobacter pylori eradication?
     Helicobacter. 2023 Nov 29:e13042. doi: 10.1111/hel.13042.
     PubMed     Abstract available
     
     
     
158. FENG Y, Huang Q, Luo M, Wei J, et al
     The association between Helicobacter pylori and gastrointestinal disorders during pregnancy: A Multicenter retrospective study.
     Helicobacter. 2023 Nov 27:e13032. doi: 10.1111/hel.13032.
     PubMed     Abstract available
     
     
     
159. MELO J, Cavadas B, Pereira L, Figueiredo C, et al
     Transcriptomic remodeling of gastric cells by Helicobacter pylori outer membrane vesicles.
     Helicobacter. 2023 Nov 23:e13031. doi: 10.1111/hel.13031.
     PubMed     Abstract available
     
     
     
160. LIM NR, Kim J, Chung WC
     Recurrence of Helicobacter pylori following successful eradication and clinical outcomes in Korean patients.
     Helicobacter. 2023 Nov 20:e13036. doi: 10.1111/hel.13036.
     PubMed     Abstract available
     
     
     
161. XU W, Yang B, Lin L, Lin Q, et al
     Antibiotic resistance of Helicobacter pylori in Chinese children: A multicenter study from 2016 to 2023.
     Helicobacter. 2023 Nov 20:e13038. doi: 10.1111/hel.13038.
     PubMed     Abstract available
     
     
     
162. ZHOU BG, Jiang X, Ding YB, She Q, et al
     Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
     Helicobacter. 2023 Nov 20:e13040. doi: 10.1111/hel.13040.
     PubMed     Abstract available
     
     
     
163. VERNON-ROBERTS A, Premaratne M, Wright R, Keenan JI, et al
     Profile of Helicobacter pylori infections among children in the South Island of New Zealand (2010-2021).
     Helicobacter. 2023 Nov 20:e13037. doi: 10.1111/hel.13037.
     PubMed     Abstract available
     
     
     
164. YUNLE K, Tong W, Jiyang L, Guojun W, et al
     Advances in Helicobacter pylori vaccine research: From candidate antigens to adjuvants-A review.
     Helicobacter. 2023 Nov 16:e13034. doi: 10.1111/hel.13034.
     PubMed     Abstract available
     
     
     
165. FANI T, Ioannis TG
     Letter to the Editor regarding the article: "Forty years of Helicobacter pylori infection and changes in findings at esophagogastroduodenoscopy".
     Helicobacter. 2023 Nov 13:e13035. doi: 10.1111/hel.13035.
     PubMed    
     
     
     
166. LEE CT, Wu CT, Chang WL, Yang EH, et al
     The nonadherence and risk factors of eradication failure by sequential therapy as first-line anti-Helicobacter pylori treatment in real-world clinical practice.
     Helicobacter. 2023 Nov 10:e13033. doi: 10.1111/hel.13033.
     PubMed     Abstract available
     
     
     October 2023
167. YE J, Feng T, Su L, Li J, et al
     Interactions between Helicobacter pylori infection and host metabolic homeostasis: A comprehensive review.
     Helicobacter. 2023 Oct 23:e13030. doi: 10.1111/hel.13030.
     PubMed     Abstract available
     
     
     
168. YOUSEFI M, Rezaei S, Khoshbaten M, Sarmasti M, et al
     Cost-effectiveness analysis of different screening strategies for helicobacter pylori infection in Iran: A model-based evaluation.
     Helicobacter. 2023 Oct 15:e13027. doi: 10.1111/hel.13027.
     PubMed     Abstract available
     
     
     
169. GAO W, Zhu M, Yin Y, Zhang X, et al
     Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta-analysis of RCTs.
     Helicobacter. 2023 Oct 15:e13022. doi: 10.1111/hel.13022.
     PubMed     Abstract available
     
     
     
170. TAN W, Liu Y, Shi Z, Zheng B, et al
     Information quality of videos related to Helicobacter pylori infection on TikTok: Cross-sectional study.
     Helicobacter. 2023 Oct 12:e13029. doi: 10.1111/hel.13029.
     PubMed     Abstract available
     
     
     
171. OKIMOTO T, Ando T, Sasaki M, Ono S, et al
     Antimicrobial-resistant Helicobacter pylori in Japan: Report of nationwide surveillance for 2018-2020.
     Helicobacter. 2023 Oct 12:e13028. doi: 10.1111/hel.13028.
     PubMed     Abstract available
     
     
     
172. O'CONNOR HJ
     Forty years of Helicobacter pylori infection and changes in findings at esophagogastroduodenoscopy.
     Helicobacter. 2023 Oct 11:e13026. doi: 10.1111/hel.13026.
     PubMed     Abstract available
     
     
     
173. WU S, Chen Y, Chen Z, Wei F, et al
     Reactive oxygen species and gastric carcinogenesis: The complex interaction between Helicobacter pylori and host.
     Helicobacter. 2023 Oct 5:e13024. doi: 10.1111/hel.13024.
     PubMed     Abstract available
     
     
     
174. DORE MP, Erre GL, Piroddu J, Pes GM, et al
     Helicobacter pylori infection and rheumatoid arthritis as risk enhancers' factors for atherosclerotic cardiovascular diseases.
     Helicobacter. 2023 Oct 4:e13025. doi: 10.1111/hel.13025.
     PubMed     Abstract available
     
     
     September 2023
175. VESGA FJ, Beltran-Benavides AR, Marquez-Duque AM, Venegas C, et al
     Helicobacter pylori virulence genotypes in Bogota River and wastewater treatment plants in Colombia.
     Helicobacter. 2023 Sep 27:e13023. doi: 10.1111/hel.13023.
     PubMed     Abstract available
     
     
     
176. RATANA-AMORNPIN S, Sanglutong L, Eiamsitrakoon T, Siramolpiwat S, et al
     Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan.
     Helicobacter. 2023 Sep 18:e13019. doi: 10.1111/hel.13019.
     PubMed     Abstract available
     
     
     
177. LI Y, Ouyang Y, He C
     Research trends on the relationship between Helicobacter pylori and microbiota: A bibliometric analysis.
     Helicobacter. 2023 Sep 11:e13021. doi: 10.1111/hel.13021.
     PubMed     Abstract available
     
     
     
178. ZHANG X, Zhang K, Yan L, Wang P, et al
     The role of toll-like receptors in immune tolerance induced by Helicobacter pylori infection.
     Helicobacter. 2023 Sep 10:e13020. doi: 10.1111/hel.13020.
     PubMed     Abstract available
     
     
     
179. GONG X, Shen L, Xie J, Liu D, et al
     Helicobacter pylori infection reduces the efficacy of cancer immunotherapy: A systematic review and meta-analysis.
     Helicobacter. 2023 Sep 3:e13011. doi: 10.1111/hel.13011.
     PubMed     Abstract available
     
     
     August 2023
180. LIN K, Huang L, Wang Y, Li K, et al
     Efficacy of genotypic susceptibility-guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta-analysis.
     Helicobacter. 2023 Aug 27:e13015. doi: 10.1111/hel.13015.
     PubMed     Abstract available
     
     
     
181. QUACH DT, Vilaichone RK, Luu MN, Lee YY, et al
     Real-world practice of Helicobacter pylori management: A survey among physicians in Southeast Asia.
     Helicobacter. 2023 Aug 27:e13018. doi: 10.1111/hel.13018.
     PubMed     Abstract available
     
     
     
182. YU Z, Zhang X, Zhao Q, Yan X, et al
     Urolithin B alleviates Helicobacter pylori-induced inflammation and oxidative stress in mice.
     Helicobacter. 2023 Aug 25:e13016. doi: 10.1111/hel.13016.
     PubMed     Abstract available
     
     
     
183. ISMAIL NI, Nawawi KNM, Hsin DCC, Hao KW, et al
     Probiotic containing Lactobacillus reuteri DSM 17648 as an adjunct treatment for Helicobacter pylori infection: A randomized, double-blind, placebo-controlled trial.
     Helicobacter. 2023 Aug 23:e13017. doi: 10.1111/hel.13017.
     PubMed     Abstract available
     
     
     
184. ZHU F, Zhang X, Li P, Zhu Y, et al
     Effect of Helicobacter pylori eradication on gastric precancerous lesions: A systematic review and meta-analysis.
     Helicobacter. 2023 Aug 21:e13013. doi: 10.1111/hel.13013.
     PubMed     Abstract available
     
     
     
185. SU NY, Shi Q, Mei H, Hu J, et al
     Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual therapy in eradicating primary Helicobacter pylori infection: A propensity score matching analysis.
     Helicobacter. 2023 Aug 10:e13003. doi: 10.1111/hel.13003.
     PubMed     Abstract available
     
     
     
186. BAWAND R, Ghiasian M, Samadyan M, Qaderi S, et al
     Association of Helicobacter pylori with migraine headaches and the effects of this infection and its eradication on the migraine characteristics in adults: A comprehensive systematic review and meta-analysis.
     Helicobacter. 2023 Aug 2:e13010. doi: 10.1111/hel.13010.
     PubMed     Abstract available
     
     
     July 2023
187. DU RC, Ouyang YB, Lu NH, Hu Y, et al
     Research trends on vonoprazan-based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023.
     Helicobacter. 2023 Jul 29:e13012. doi: 10.1111/hel.13012.
     PubMed     Abstract available
     
     
     
188. NGUYEN TC, Le GKN, Pham DTH, Pham BV, et al
     Antibiotic resistance and heteroresistance in Helicobacter pylori isolates from symptomatic Vietnamese children: A prospective multicenter study.
     Helicobacter. 2023 Jul 27:e13009. doi: 10.1111/hel.13009.
     PubMed     Abstract available
     
     
     
189. LIMA IS, da Silva TM, Weiss S, Homuth G, et al
     Genome-wide association study of Helicobacter pylori serological status in Latin American children.
     Helicobacter. 2023 Jul 27:e13008. doi: 10.1111/hel.13008.
     PubMed     Abstract available
     
     
     
190. DU RC, Zhang Y, Wang MH, Lu NH, et al
     TikTok and Bilibili as sources of information on Helicobacter pylori in China: A content and quality analysis.
     Helicobacter. 2023 Jul 15:e13007. doi: 10.1111/hel.13007.
     PubMed     Abstract available
     
     
     
191. KOTILEA K, Iliadis E, Nguyen J, Salame A, et al
     Antibiotic resistance, heteroresistance, and eradication success of Helicobacter pylori infection in children.
     Helicobacter. 2023 Jul 4:e13006. doi: 10.1111/hel.13006.
     PubMed     Abstract available
     
     
     June 2023
192. HASSAN SS, Nader M, Nagy M, Mohamed M, et al
     Antimicrobial screening involving Helicobacter pylori of nano-therapeutic compounds based on the amoxicillin antibiotic drug.
     Helicobacter. 2023 Jun 30:e13004. doi: 10.1111/hel.13004.
     PubMed     Abstract available
     
     
     
193. ZHANG Y, Zhao Z, Fu W, Ding S, et al
     The expression and function of the B7 family in Helicobacter pylori infection and gastric carcinogenesis process.
     Helicobacter. 2023 Jun 29:e12999. doi: 10.1111/hel.12999.
     PubMed     Abstract available
     
     
     
194. ZHANG Z, Chen X, Li B, Xia T, et al
     Helicobacter pylori induces urease subunit B-specific CD8(+) T cell responses in infected individuals via cytosolic pathway of cross-presentation.
     Helicobacter. 2023 Jun 29:e13005. doi: 10.1111/hel.13005.
     PubMed     Abstract available
     
     
     
195. BARREYRO FJ, Maiorana F, Caronia MV, Elizondo K, et al
     Association between genetic polymorphisms of NOD1, Interleukin-1B, and cagA strain with low-grade duodenal eosinophilia in Helicobacter pylori-related dyspepsia.
     Helicobacter. 2023 Jun 23:e13002. doi: 10.1111/hel.13002.
     PubMed     Abstract available
     
     
     
196. ISMAIL M, Majaliwa ND, Vale FF, Cumbana R, et al
     Molecular detection of Helicobacter pylori and its genotypic antimicrobial resistance patterns in dyspeptic Mozambican patients.
     Helicobacter. 2023 Jun 20:e13000. doi: 10.1111/hel.13000.
     PubMed     Abstract available
     
     
     
197. KATSANDE PM, Nguyen VD, Nguyen TLP, Nguyen TKC, et al
     Prophylactic immunization to Helicobacter pylori infection using spore vectored vaccines.
     Helicobacter. 2023 Jun 14:e12997. doi: 10.1111/hel.12997.
     PubMed     Abstract available
     
     
     
198. LEE SY, Kim JH, Sung IK, Park HS, et al
     Twice-daily intake of bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: A retrospective study on 10-day, 14-day, and half-dose antibiotic therapy.
     Helicobacter. 2023 Jun 9:e12998. doi: 10.1111/hel.12998.
     PubMed     Abstract available
     
     
     May 2023
199. JIANG F, Ju C, Guo CG, Cheung KS, et al
     Risk of hospitalization for upper gastrointestinal bleeding in Helicobacter pylori eradicated patients newly started on warfarin or direct oral anticoagulants: A population-based cohort study.
     Helicobacter. 2023 May 29:e12990. doi: 10.1111/hel.12990.
     PubMed     Abstract available
     
     
     
200. ZENG R, Li X, Wang F, Xie J, et al
     Reinforced medication adherence improves Helicobacter pylori eradication rate in developing countries: A systematic review and meta-analysis of randomized controlled trials.
     Helicobacter. 2023 May 17:e12989. doi: 10.1111/hel.12989.
     PubMed     Abstract available
     
     
     
201. HU J, Mei H, Su NY, Sun WJ, et al
     Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China.
     Helicobacter. 2023 May 9:e12970. doi: 10.1111/hel.12970.
     PubMed     Abstract available
     
     
     
202. KARAYIANNIS I, Martinez-Gonzalez B, Kontizas E, Kokkota AV, et al
     Induction of MMP-3 and MMP-9 expression during Helicobacter pylori infection via MAPK signaling pathways.
     Helicobacter. 2023 May 4:e12987. doi: 10.1111/hel.12987.
     PubMed     Abstract available
     
     
     
203. WANG R, Huang S, Gan P, Pan X, et al
     States and hotspots in Helicobacter pylori research from 2002 to 2021: A bibliometric analysis.
     Helicobacter. 2023 May 3:e12986. doi: 10.1111/hel.12986.
     PubMed     Abstract available
     
     
     April 2023
204. MCNULTY CAM
     The first 5 years of Helicobacter pylori research-With an emphasis on the United Kingdom.
     Helicobacter. 2023 Apr 27:e12982. doi: 10.1111/hel.12982.
     PubMed     Abstract available
     
     
     
205. LI M, Gao N, Wang S, Guo Y, et al
     Bibliometric analysis of Helicobacter pylori resistance-from 2002 to 2022.
     Helicobacter. 2023 Apr 27:e12983. doi: 10.1111/hel.12983.
     PubMed     Abstract available
     
     
     
206. ZANG H, Wang J, Wang H, Guo J, et al
     Metabolic alterations in patients with Helicobacter pylori-related gastritis: The H. pylori-gut microbiota-metabolism axis in progression of the chronic inflammation in the gastric mucosa.
     Helicobacter. 2023 Apr 25:e12984. doi: 10.1111/hel.12984.
     PubMed     Abstract available
     
     
     
207. KIM JS, Ko W, Chung JW, Kim TH, et al
     Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: A randomized, double-blind, active-controlled study.
     Helicobacter. 2023 Apr 21:e12977. doi: 10.1111/hel.12977.
     PubMed     Abstract available
     
     
     
208. HAN X, Yu X, Gao X, Wang X, et al
     Quantitative PCR of string-test collected gastric material: A feasible approach to detect Helicobacter pylori and its resistance against clarithromycin and levofloxacin for susceptibility-guided therapy.
     Helicobacter. 2023 Apr 17:e12985. doi: 10.1111/hel.12985.
     PubMed     Abstract available
     
     
     
209. HU S, Zhou Y, Deng Y, Bo Y, et al
     Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia.
     Helicobacter. 2023 Apr 11:e12960. doi: 10.1111/hel.12960.
     PubMed     Abstract available
     
     
     
210. SOH H, Kim N, Moon J, Lee HM, et al
     Gastric mucosal swab as an alternative to biopsy for Helicobacter pylori detection.
     Helicobacter. 2023 Apr 7:e12980. doi: 10.1111/hel.12980.
     PubMed     Abstract available
     
     
     
211. YU H, Li J, Liu X, Chen Z, et al
     Helicobacter pylori bacteremia presenting as seizure and unconsciousness: The brief case.
     Helicobacter. 2023 Apr 5:e12973. doi: 10.1111/hel.12973.
     PubMed     Abstract available
     
     
     
212. ZENG R, Xie Y
     Inquiry about methodology used to isolate multiple Helicobacter pylori strains from the same patient.
     Helicobacter. 2023 Apr 3:e12981. doi: 10.1111/hel.12981.
     PubMed    
     
     
     
213. KOSUNEN TU, Nieminen AA, Kokkola A, Arkkila P, et al
     Incidence of gastrointestinal malignancies increases in persons received eradication therapy for Helicobacter pylori: A cohort study.
     Helicobacter. 2023 Apr 3:e12979. doi: 10.1111/hel.12979.
     PubMed     Abstract available
     
     
     
214. COLLIN A, Mion F, Kefleyesus A, Beets C, et al
     Critical appraisal of international guidelines for the management of Helicobacter pylori infection in case of dyspepsia.
     Helicobacter. 2023;28:e12952.
     PubMed     Abstract available
     
     
     March 2023
215. XIE Y, Hu Y, Zhu Y, Wang H, et al
     Colloidal bismuth pectin-containing quadruple therapy as the first-line treatment of Helicobacter pylori infection: A multicenter, randomized, double-blind, non-inferiority clinical trial.
     Helicobacter. 2023 Mar 31:e12978. doi: 10.1111/hel.12978.
     PubMed     Abstract available
     
     
     
216. KWON YM, Kim SJ, Lee JG, Lee SP, et al
     Effects of prior antibiotic use on clarithromycin resistance in Helicobacter pylori.
     Helicobacter. 2023 Mar 28:e12974. doi: 10.1111/hel.12974.
     PubMed     Abstract available
     
     
     
217. SUN L, Zheng H, Qiu M, Hao S, et al
     Helicobacter pylori infection and risk of cardiovascular disease.
     Helicobacter. 2023 Mar 28:e12967. doi: 10.1111/hel.12967.
     PubMed     Abstract available
     
     
     
218. LYU T, Cheung KS, Deng Z, Ni L, et al
     Whole genome sequencing reveals novel genetic mutations of Helicobacter pylori associating with resistance to clarithromycin and levofloxacin.
     Helicobacter. 2023 Mar 25:e12972. doi: 10.1111/hel.12972.
     PubMed     Abstract available
     
     
     
219. IKEDA N, Shoji H, Ikuse T, Ohkawa N, et al
     A case of neonatal thrombocytopenia due to maternal Helicobacter pylori-associated immune thrombocytopenia.
     Helicobacter. 2023 Mar 23:e12976. doi: 10.1111/hel.12976.
     PubMed     Abstract available
     
     
     
220. KIM SB, Kim N, Park J, Hwang IC, et al
     Preventive effect of Helicobacter pylori eradication on the coronary heart diseases depending on age and sex with a median follow-up of 51 months.
     Helicobacter. 2023 Mar 22:e12969. doi: 10.1111/hel.12969.
     PubMed     Abstract available
     
     
     
221. ERGENC M, Uprak TK
     YouTube as a source of information on Helicobacter pylori: Content and quality analysis.
     Helicobacter. 2023 Mar 21:e12971. doi: 10.1111/hel.12971.
     PubMed     Abstract available
     
     
     
222. SHENG C, Sun L, Lyu Z, Li L, et al
     Development of a modified ABC method among Helicobacter pylori infected but serum pepsinogen test-negative individuals.
     Helicobacter. 2023 Mar 20:e12966. doi: 10.1111/hel.12966.
     PubMed     Abstract available
     
     
     
223. ANTUNES R, Oleastro M, Nogueira JP, Lopes AI, et al
     Time trend prevalence of helicobacter pylori infection and endoscopic findings in symptomatic children in Portugal: A retrospective study based on three time points in 2009, 2014, and 2019.
     Helicobacter. 2023 Mar 10:e12963. doi: 10.1111/hel.12963.
     PubMed     Abstract available
     
     
     
224. YU T, Lu T, Deng W, Yao D, et al
     Microbiome and function alterations in the gastric mucosa of asymptomatic patients with Helicobacter pylori infection.
     Helicobacter. 2023 Mar 8:e12965. doi: 10.1111/hel.12965.
     PubMed     Abstract available
     
     
     February 2023
225. REN X, Shi Y, Suo B, Yao X, et al
     Individualized diagnosis and eradication therapy for Helicobacter pylori infection based on gene detection of clarithromycin resistance in stool specimens: A systematic review and meta-analysis.
     Helicobacter. 2023 Feb 24:e12958. doi: 10.1111/hel.12958.
     PubMed     Abstract available
     
     
     
226. KAJIHARA Y, Shimoyama T, Mizuki I
     Evaluation of the effects of a proton pump inhibitor on Helicobacter pylori stool antigen testing.
     Helicobacter. 2023 Feb 24:e12961. doi: 10.1111/hel.12961.
     PubMed     Abstract available
     
     
     
227. ARINO-PEREZ I, Martinez-Dominguez SJ, Alfaro Almajano E, Carrera-Lasfuentes P, et al
     Mistakes in the diagnosis and treatment of Helicobacter pylori infection in daily clinical practice.
     Helicobacter. 2023 Feb 24:e12957. doi: 10.1111/hel.12957.
     PubMed     Abstract available
     
     
     
228. HE T, Zhang F, Zhang J, Wei S, et al
     UreB immunodominant epitope-specific CD8(+) T-cell responses were beneficial in reducing gastric symptoms in Helicobacter pylori-infected individuals.
     Helicobacter. 2023 Feb 24:e12959. doi: 10.1111/hel.12959.
     PubMed     Abstract available
     
     
     
229. MACEDO SILVA V, Lima Capela T, Freitas M, Boal Carvalho P, et al
     A "new" option in Helicobacter pylori eradication: High-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting.
     Helicobacter. 2023 Feb 24:e12962. doi: 10.1111/hel.12962.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Peptic Ulcer is free of charge.